Ferric citrate
- Generic Name
- Ferric citrate
- Brand Names
- Auryxia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H32Fe4O31
- CAS Number
- -
- Unique Ingredient Identifier
- Q91187K011
- Background
Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.
Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.
- Indication
Tetraferric tricitrate decahydrate is indicated to control serum phosphorous in adults with chronic kidney disease who require dialysis. Tetraferric tricitrate decahydrate is also indicated to treat iron deficiency anemia in adults with chronic kidney disease who are not on dialysis.
- Associated Conditions
- Hyperphosphataemia, Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
- Conditions
- Interventions
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Denver Nephrologists, P.C.
- Target Recruit Count
- 200
- Registration Number
- NCT02492620
- Locations
- 🇺🇸
Denver Nephrologists, P.C., Denver, Colorado, United States
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT02268994
- Locations
- 🇺🇸
California Renal Research, Glendale, California, United States
🇺🇸Academic Medical Research Institute, Inc, Los Angeles, California, United States
🇺🇸Kidney Care Associates, LLC, Augusta, Georgia, United States
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 149
- Registration Number
- NCT01736397
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT01554982
- Locations
- 🇺🇸
Kidney Care Associates, LLC, Augusta, Georgia, United States
🇺🇸Asheville Kidney Center, Asheville, North Carolina, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT01503736
- Locations
- 🇨🇳
Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital, New Taipei City, Taiwan
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT01074125
- Locations
- 🇺🇸
Centre Point Dialysis, West Allis, Wisconsin, United States
🇺🇸Western Nephrology, Westminster, Colorado, United States
🇺🇸Pines Clinical Research, Inc., Pembroke Pines, Florida, United States
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00967993
- Locations
- 🇮🇱
Barzilai Medical Center Ben-Gurion University, Ashkelon, Israel
🇮🇱Hadassah University Hospital-Ein Kerem, Jerusalem, Israel
🇮🇱Assaf Haraofeh Medical Center, Zerifin, Israel
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT00648167
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.